Acute Bipolar DepressionPhase 3QUALITYNCT00883493
Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression
A Phase 3 study testing Quetiapine fumarate XR and Lithium carbonate in people with Acute Bipolar Depression, run by AstraZeneca at 24 sites in 9 countries.
Trial summary
The purpose of this study is to compare the efficacy of quetiapine fumarate monotherapy with quetiapine fumarate in combination with lithium in the treatment of a major depressive episode in patients with bipolar disorder. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Acute Bipolar Depression
- What is being tested?
- Quetiapine fumarate XR and Lithium carbonate
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 421 participants
- Where
- 24 sitesin 9 countries
- Study dates
- Apr 2009to Mar 2011
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Outpatients that meet the diagnostic criteria for bipolar disorder I and bipolar disorder II with the most recent episode depressed
- The total score of the scale that's used for the evaluation of depression (HAM-D) should be ≥20
- The total score of the scale that' used for the evaluation of mania (YMRS) should be ≤12
Who cannot join
- Patients with a current DSM-IV-TR Axis I disorder other than bipolar disorder within 6 months of enrollment. Patients who pose a current serious suicidal or homicidal risk
- Use of drugs that induce or inhibit the hepatic metabolizing enzymes within 14 days before randomisation
- Patients who are unable to discontinue all psychoactive medications, including antidepressants, antipsychotics, and mood stabilizers at least 7 days prior to randomisation and consistent with the pharmacokinetics of the drug
Trial locations and contacts
24 sites in 9 countries.
24 sites in 9 countries
Turkey (Türkiye)7 sites
Research Site
Ankara, Turkey
Research Site
Elâzığ, Turkey
Research Site
Istanbul, Turkey
Research Site
Izmir, Turkey
Research Site
Kocaeli, Turkey
Research Site
Malatya, Turkey
Research Site
Manisa, Turkey
Argentina4 sites
Research Site
Caba
Research Site
Godoy Cruz, Mendoza Province
Research Site
La Plata, Buenos Aires
Research Site
Mendoza, Mendoza Province
Mexico4 sites
Research Site
Durango
Research Site
Monterrey, Nuevo León
Research Site
Monterrey
Research Site
San Luis Potosí City, San Luis Potosí
Brazil3 sites
Research Site
Aparecida de Goiânia, Goiás
Research Site
Rio de Janeiro, Rio de Janeiro
Research Site
São Paulo, São Paulo
Colombia2 sites
Research Site
Bogota D.c, Cundinamarca
Research Site
Medellín, Antioquia
About this study
Official title: A Randomised, Multi-Centre Study to Compare the Efficacy and Safety of Extended Release Quetiapine Fumarate (Seroquel XR TM) Tablets as Mono-Therapy or in Combination With Lithium in the Treatment of Patients With Acute Bipolar Depression
The purpose of this study is to compare the efficacy of quetiapine fumarate monotherapy with quetiapine fumarate in combination with lithium in the treatment of a major depressive episode in patients with bipolar disorder.
- Conditions
- Acute Bipolar Depression
- Being tested
- Quetiapine fumarate XR, Lithium carbonate
- Keywords
- Acute bipolar depression, Lithium carbonate, quetiapine fumarate, MADRS
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quetiapine fumarate XRDrug
Also called SEROQUEL XR
Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
Lithium carbonateDrug
Also called LITHURIL Tb in TURKEY, LITOCARB in PERU
Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day
| Study group | Role | What they receive |
|---|---|---|
| Quetiapin fumarate XR | Experimental | Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg. Receives: Drug: Quetiapine fumarate XR |
| Quetiapin fumarate XR+Lithium carbonate | Experimental | Quetiapine XR will be administered like monotherapy arm. Lithium will be administered twice daily from Day 1 to Day 56. Receives: Drug: Quetiapine fumarate XR; Drug: Lithium carbonate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.
The change of MADRS Total Score from baseline to the end of treatment was calculated by subtracting the MADRS Total Score assessed at week 8 from the baseline one (Baseline - 8 weeks).
The MADRS is a 10-item scale that evaluates the core symptoms and cognitive features of clinical depression. Each MADRS item is rated on a 0 to 6 scale. The MADRS Total score ranges from 0 (min) to 60 (max). Higher MADRS scores indicate higher levels of depressive symptoms.
Measured: Baseline, 8 weeks
Secondary outcomes (9)
Response Rate for MADRS.
Response rate defined as the percentage of patients with a ≥50% reduction from baseline in the MADRS total score to the final assessment at week 8.
The MADRS is a 10-item scale that evaluates the core symptoms and cognitive features of clinical depression. Each MADRS item is rated on a 0 to 6 scale. The MADRS Total score ranges from 0 (min) to 60 (max). Higher MADRS scores indicate higher levels of depressive symptoms.
Measured: baseline, week 8
Hamilton Rating Scale for Depression (HAM-D) Total Score.
The mean change of HAM-D Total Score from baseline to the end of treatment was calculated by subtracting the HAM-D Total Score assessed at week 8 from the baseline one (Baseline - week 8).
HAM-D is a multiple choice questionnaire used to rate the severity of a patient's major depression. It consists of 17 different items with possible scores from 0 to 4 or 0 to 2 or 0 to 6 depending on the items. Sum the total of all seventeen items gives the HAM-D Total Score, which may range from 0 (min) to 53 (max). The higher the score, the more severe the depression.
Measured: Baseline, 8 Weeks
Change in Hamilton Rating Scale for Anxiety (HAM-A) Total Score
The mean change in HAM-A total score from baseline to final assessment was calculated by subtracting the HAM-A Total score assessed at week 8 from the total score assessed at the baseline (baseline - week 8).
The HAM-A is a 14-item scale that assesses anxiety symptoms of anxiety such as "anxious mood", "tension" or "fears". Each item is scored on a 5-point scale, ranging from 0=not present to 4=severe. Sum the scores from all 14 parameters gives the HAM-A Total Score which may range from 0 (min) to 56 (max).
Measured: baseline, 8 weeks
Change in the Clinical Global Impression Severity (CGI-S) Score.
The reported mean change in the CGI-S score was calculated as baseline - week 8.
CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment. A patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
Measured: baseline, 8 weeks
Change in Young Mania Rating Scale (YMRS) Total Score.
The YMRS is a rating scale to assess manic symptoms. The scale has 11 items and is based upon patient's subjective report of his or hers clinical condition over the previous 48 hours.
The mean change in YMRS Total score reported was calculated as baseline - week 8.
The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).
Measured: baseline, 8 weeks
Change in the Pittsburgh Sleep Quality Index (PSQI)Total Score.
The mean change in PSQI score from baseline to final assessment at week 8 was calculated as baseline - week 8.
PSQI evaluates 7 areas of quality and pattern of sleep: sleep quality, duration getting to sleep, sleep duration, sleep adequacy, sleep disturbance, use of sleeping pill, and somnolence). Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality.
Measured: Baseline, 8 weeks
Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Score.
The mean change in (Q-LES-Q-Short Form) Total Score from baseline to week 8 was calculated by subtracting the 8 week value from baseline value (baseline - week 8).
The Q-LES-Q-SF is a patient self assessment questionnaire consisting of 16 self-rated questions (1 being very poor - 5 very good); the first 14 will be incorporated into a total score. Higher scores indicate better quality of life.
Measured: baseline, 8 weeks
Change in the Sheehan Disability Scale (SDS) Total Score.
The mean change in the SDS Total score from baseline to week 8 (baseline- week 8).
Sheehan Disability Scale is a 5 item scale, with a visual analog scale evaluating work/school work, social life and family life ranging from 0 to a maximum score of 30. Each one of the 3 domains is rated from 0-10 (no impairment to most severe impairment) with evaluation of not at all (0), mild (1-3), moderate (4-6), marked (7-9) and extreme (10) disability. A total score will be calculated. A score of 30 indicates most severe impairment.
Measured: baseline, 8 weeks
Treatment Satisfaction Questionnaire (TSQ) Scores.
The 14-item TAQ questionnaire evaluates the patient's overall level of satisfaction with the study medication, the effectiveness, side effects and convenience of the medication.
Effectiveness, side effects, convenience and global satisfaction is rated on a scale of 0 being the worst and 100 being very effective, no side effects or very convenient or very satisfied. Overall satisfaction is rated over a score of 5 and 5 being the best overall satisfaction.
Measured: baseline, 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2009 (estimated)
- Study startApr 2009
- Primary completionMar 2011
- Study completionMar 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Acute Bipolar DepressionStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 421 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Simavi Vahip, Prof. Dr., Principal investigator, Ege University Faculty of Medicine Psychiatry Department İzmir
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00883493
- Sponsor's protocol ID
- D1443L00055
- Acronym
- QUALITY
- Status last verified
- Jul 2012
- First submitted
- 16 Apr 2009
- Last updated
- 11 Jul 2012
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jul 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised, Multi-Centre Study to Compare the Efficacy and Safety of Extended Release Quetiapine Fumarate (Seroquel XR TM) Tablets as Mono-Therapy or in Combination With Lithium in the Treatment of Patients With Acute Bipolar Depression
- ClinicalTrials.gov ID
- NCT00883493
- Acronym / sponsor ID
- QUALITY / D1443L00055
- Conditions
- Acute Bipolar Depression
- Keywords
- Acute bipolar depression, Lithium carbonate, quetiapine fumarate, MADRS
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 421 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- Apr 2009
- Primary completion
- Mar 2011 (actual)
- Study completion
- Mar 2011 (actual)
- First posted
- 17 Apr 2009 (estimated)
- Results
- Posted 29 Jun 2012
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to compare the efficacy of quetiapine fumarate monotherapy with quetiapine fumarate in combination with lithium in the treatment of a major depressive episode in patients with bipolar disorder.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Quetiapin fumarate XR | Experimental | Drug: Quetiapine fumarate XRQuetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg. |
| Quetiapin fumarate XR+Lithium carbonate | Experimental | Drug: Quetiapine fumarate XR, Drug: Lithium carbonateQuetiapine XR will be administered like monotherapy arm. Lithium will be administered twice daily from Day 1 to Day 56. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Outpatients that meet the diagnostic criteria for bipolar disorder I and bipolar disorder II with the most recent episode depressed
- The total score of the scale that's used for the evaluation of depression (HAM-D) should be ≥20
- The total score of the scale that' used for the evaluation of mania (YMRS) should be ≤12
Key exclusion criteria (3 listed)
- Patients with a current DSM-IV-TR Axis I disorder other than bipolar disorder within 6 months of enrollment. Patients who pose a current serious suicidal or homicidal risk
- Use of drugs that induce or inhibit the hepatic metabolizing enzymes within 14 days before randomisation
- Patients who are unable to discontinue all psychoactive medications, including antidepressants, antipsychotics, and mood stabilizers at least 7 days prior to randomisation and consistent with the pharmacokinetics of the drug
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quetiapine fumarate XRAlso: SEROQUEL XRQuetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg. | Drug | Quetiapin fumarate XR, Quetiapin fumarate XR+Lithium carbonate |
| Lithium carbonateAlso: LITHURIL Tb in TURKEY, LITOCARB in PERUTwice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day | Drug | Quetiapin fumarate XR+Lithium carbonate |
Primary outcome
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.
Time frame: Baseline, 8 weeks
The change of MADRS Total Score from baseline to the end of treatment was calculated by subtracting the MADRS Total Score assessed at week 8 from the baseline one (Baseline - 8 weeks). The MADRS is a 10-item scale that evaluates the core symptoms and cognitive features of clinical depression. Each MADRS item is rated on a 0 to 6 scale. The MADRS Total score ranges from 0 (min) to 60 (max). Higher MADRS scores indicate higher levels of depressive symptoms.
9 secondary outcomes
Response Rate for MADRS.
Time frame: baseline, week 8
Hamilton Rating Scale for Depression (HAM-D) Total Score.
Time frame: Baseline, 8 Weeks
Change in Hamilton Rating Scale for Anxiety (HAM-A) Total Score
Time frame: baseline, 8 weeks
Change in the Clinical Global Impression Severity (CGI-S) Score.
Time frame: baseline, 8 weeks
Change in Young Mania Rating Scale (YMRS) Total Score.
Time frame: baseline, 8 weeks
Change in the Pittsburgh Sleep Quality Index (PSQI)Total Score.
Time frame: Baseline, 8 weeks
Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Score.
Time frame: baseline, 8 weeks
Change in the Sheehan Disability Scale (SDS) Total Score.
Time frame: baseline, 8 weeks
Treatment Satisfaction Questionnaire (TSQ) Scores.
Time frame: baseline, 8 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jul 2012.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Acute Bipolar Depression
RecruitingPhase 4
Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)
Depression, Bipolar
RecruitingObservational study
Immune Mechanisms of Antipsychotic Treatment Response
Psychosis
RecruitingObservational study
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Post-Acute COVID-19 Syndrome, ME/CFS
RecruitingPhase 1/2
Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression
Bipolar Depression
RecruitingPhase 3
Cannabidiol for Bipolar Depression (CBD-BD)
Bipolar Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Simavi Vahip, Prof. Dr. principal investigator
Ege University Faculty of Medicine Psychiatry Department İzmir
24 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Quetiapine fumarate XR and Lithium carbonate in people with Acute Bipolar Depression, run by AstraZeneca at 24 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jul 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 24 sites in Turkey (Türkiye), Argentina, Mexico, Brazil, Colombia and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 29 Jun 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. (time frame: Baseline, 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2012.